Novartis Ag (NVS) Profit After Tax (QoQ) (2009 - 2023)
Novartis Ag (NVS) Profit After Tax (QoQ) (2009 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -99.95% |
| Mar 31, 2023 | 127,680.56% |
| Dec 31, 2022 | 244.54% |
| Sep 30, 2022 | -32.98% |
| Jun 30, 2022 | -100.00% |
| Mar 31, 2022 | 686,241.78% |
| Dec 31, 2021 | 254.11% |
| Sep 30, 2021 | -51.68% |
| Jun 30, 2021 | -99.98% |
| Mar 31, 2021 | 346,467.05% |
| Dec 31, 2020 | -99.98% |
| Sep 30, 2020 | 964,088.06% |
| Jun 30, 2020 | 862.37% |
| Jun 30, 2019 | 1,262.73% |
| Mar 31, 2019 | -78.16% |
| Dec 31, 2018 | 37.32% |
| Sep 30, 2018 | -78.58% |
| Jun 30, 2018 | 1,138.92% |
| Mar 31, 2018 | -91.17% |
| Dec 31, 2017 | 333.34% |